SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+11.91%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$173M
AUM Growth
+$173M
(+84,096%)
Cap. Flow
+$22.9M
Cap. Flow
% of AUM
13.3%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
115
New
19
Increased
26
Reduced
33
Closed
31
Top Buys
| 1 |
Fulcrum Therapeutics
FULC
|
$5.24M |
| 2 |
Cogent Biosciences
COGT
|
$4.03M |
| 3 |
Cerus
CERS
|
$3.66M |
| 4 |
Arvinas
ARVN
|
$3.06M |
| 5 |
NextCure
NXTC
|
$2.94M |
Top Sells
Sector Composition
| 1 | Healthcare | 93.23% |
| 2 | Financials | 4.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Celldex Therapeutics
CLDX
$1.47B
| $2.07M | 1.17% | 38,243 +28,322 | +285% | +$1.53M |
|
|
ELOX
27
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
| $2.05M | 1.16% | 1,259,840 -627,699 | -33% | -$1.02M |
|
28
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $2.05M | 1.16% | 388,632 +130,674 | +51% | +$689K |
|
|
SGEN
29
DELISTED
Seagen Inc. Common Stock
SGEN
| $2M | 1.13% | 11,749 +6,017 | +105% | +$1.02M |
|
30
Erasca
ERAS
$445M
| $1.98M | 1.12% | +93,122 | New | +$1.98M |
|
|
OTIC
31
DELISTED
Otonomy, Inc.
OTIC
| $1.95M | 1.1% | 1,017,048 +63,614 | +7% | +$122K |
|
32
VistaGen Therapeutics
VTGN
$102M
| $1.94M | 1.1% | 707,733 +92,186 | +15% | +$253K |
|
33
Seres Therapeutics
MCRB
$166M
| $1.91M | 1.08% | 274,833 +210,918 | +330% | +$1.47M |
|
34
Benitec Biopharma
BNTC
$348M
| $1.78M | 1.01% | 498,009 +30,753 | +7% | +$110K |
|
35
Cytokinetics
CYTK
$4.23B
| $1.76M | 1% | +49,309 | New | +$1.76M |
|
36
Viridian Therapeutics
VRDN
$1.5B
| $1.75M | 0.99% | 106,078 +77,679 | +274% | +$1.28M |
|
|
LHDX
37
DELISTED
Lucira Health, Inc. Common Stock
LHDX
| $1.68M | 0.95% | +220,758 | New | +$1.68M |
|
38
Zentalis Pharmaceuticals
ZNTL
$122M
| $1.59M | 0.9% | 23,855 -10,870 | -31% | -$725K |
|
39
Stereotaxis
STXS
$261M
| $1.57M | 0.89% | 291,696 -14,708 | -5% | -$79.1K |
|
|
JNCE
40
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.55M | 0.88% | 208,559 -42,085 | -17% | -$313K |
|
41
PolyPid
PYPD
$53.3M
| $1.43M | 0.81% | 183,230 +28,664 | +19% | +$223K |
|
|
ADMS
42
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $1.41M | 0.8% | 288,042 -250,702 | -47% | -$1.23M |
|
43
EyePoint Pharmaceuticals
EYPT
$797M
| $1.35M | 0.76% | 129,290 -113,019 | -47% | -$1.18M |
|
|
VRAY
44
DELISTED
ViewRay, Inc.
VRAY
| $1.33M | 0.75% | 185,035 +90,647 | +96% | +$654K |
|
|
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.27M | 0.72% | 37,249 -8 | -0% | -$272 |
|
46
Biogen
BIIB
$19.4B
| $1.24M | 0.7% | +4,389 | New | +$1.24M |
|
47
Compugen
CGEN
$132M
| $1.22M | 0.69% | 203,532 -5,581 | -3% | -$33.3K |
|
|
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.11M | 0.63% | 18,581 -1,996 | -10% | -$119K |
|
|
MSAC
49
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| $1.07M | 0.61% | 110,040 -263,235 | -71% | -$2.57M |
|
50
Kura Oncology
KURA
$686M
| $1.06M | 0.6% | 56,614 -25,959 | -31% | -$486K |
|